Allero Therapeutics BV

Allero Therapeutics is a Dutch biotech company founded in 2016 that is making significant strides in the development of next generation immunotherapies for immune mediated disorders. The company's proprietary SOMIT (Specific Oromucosal Immunotherapy) technology is at the forefront of this innovation, combining a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege. Their ultimate goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Recently, Allero Therapeutics secured a €2.50M grant investment on 21 October 2021 from The European Innovation Council to further advance their groundbreaking research and development efforts. As a company operating in the biotechnology and pharmaceutical industries, Allero Therapeutics is positioned at the intersection of scientific innovation and medical necessity. With its Netherlands headquarters serving as a hub for its pioneering work, the company continues to attract attention and support within the investment community for its potential to revolutionize immune disorder treatment.